An Investigation of the Consciousness Energy Healing Therapy on Physicochemical and Thermal Properties of Silver Sulfadiazine

Silver sulfadiazine is a topical sulfa drug antibiotic that is used by burn patients to prevent the bacterial infection. This study was aimed to analyze the impact of the Trivedi Effect® on the physicochemical and thermal properties of silver sulfadiazine with the help of various analytical techniques. The silver sulfadiazine sample was divided into the control and treated parts; where, no Biofield Treatment was provided to the control part, while the treated part received the Biofield Treatment remotely by a renowned Biofield Energy Healer, Dahryn Trivedi. The PXRD peak intensities and the crystallite sizes were significantly altered ranging from -75.25% to 31.21% and -8.80% to 192.76% respectively, along with 64.06% increase in the average crystallite size of the treated sample than the control sample. The particle sizes were decreased by 1.60% (d10), 2.30% (d50), 2.06% (d90), and 4.40% [D (4,3)]; therefore, the surface area was increased by 2.61% in the treated sample in contrast to the control sample. The latent heat of fusion and decomposition of the treated sample were significantly altered by -21.52% and 32.03%, respectively, compared to the control sample. Additionally, the total weight loss was reduced by 1.86%; however, the residue amount was increased by 2.88% in the treated sample compared with the control sample. Hence, the Biofield Treatment might be considered as a novel approach to generate a new polymorph of silver sulfadiazine that is more soluble, bioavailable, and thermally stable, which could be useful in designing a novel pharmaceutical formulation for the better therapeutic response against various type of bacterial disease.

The impact of the Trivedi Effect®-Consciousness Energy Healing Treatment on silver sulfadiazine was significant on the crystal morphology and structure, particle size, and thermal properties. The PXRD data showed alterations in the Bragg’s angles of the characteristic peaks of the Biofield Energy Treated sample along with the peak intensity in comparison to the untreated sample. The intensities of those peaks of the Biofield Energy Treated sample were altered ranging from -75.25% to 31.21%; while the crystallite sizes showed the significant alteration ranging from -8.80% to 192.76%, compared with the control sample. Moreover, the Biofield Energy Treated sample showed a significant increase in the average crystallite size by 64.06% compared with the untreated silver sulfadiazine sample. The particle size distribution of the Biofield Energy Treated sample also indicated significant alterations in the particle sizes after the Biofield Energy Treatment. The particle size values were reduced by 1.60%, 2.30%, 2.06%, and 4.40% at d10, d50, d90, and D (4,3), respectively compared to the control sample. Therefore, the specific surface area of the Biofield Energy Treated sample was increased by 2.61% compared to the control sample.

The ?Hfusion of the Biofield Energy Treated silver sulfadiazine was significantly decreased by 21.52% compared with the untreated sample. Nevertheless, the ?Hdecomposition of the Biofield Energy Treated sample was significantly increased by 32.03% compared to the control sample. The total weight loss analyzed from the TGA analysis showed 1.86% reduction in the Biofield Energy Treated sample that resulted in 2.88% increase in the residual amount in comparison to the untreated silver sulfadiazine. The DTG analysis showed ~2.5°C increase (0.94%) in the Tmax of the Biofield Energy Treated silver sulfadiazine sample compared with the control sample. Thus, the overall data suggests that the Trivedi Effect®-Consciousness Energy Healing Treatment might generate a novel polymorph of silver sulfadiazine which would be more soluble, absorbable, and bioavailable and thermally more stable compared with the untreated sample. Hence, the Trivedi Effect® Treated silver sulfadiazine can provide better therapeutic benefits to prevent and treat microbial infections by designing more efficacious pharmaceutical formulations.